Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q1 2026 revenue around $205M, full-year guidance raised to about $925M total global revenue, BRIUMVI execution remains strong, and technical momentum is favorable with about 16% 21-day gain and 17% in the last 5 sessions.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Support holding ⢠Resistance ceiling ⢠Weakness bounce Support Level: $53-$54 Resistance Level: $57-$59 TGTX remains constructive over the last month by holding $53-$54 support and bouncing off $52.68, but it needs a decisive reclaim of $57-$59 to turn the trend more bullish.
Sentiment & News
Key News Insights: ⢠Briumvi Demand ⢠Schizophrenia Trial ⢠Fiduciary Scrutiny TG Therapeutics is benefiting from strong Briumvi-driven growth and pipeline expansion, but ongoing fiduciary-duty investigations continue to create a legal overhang.
AI Summary
TGTX has transitioned from a speculative biotech to a real commercial story as BRIUMVI drives ~all revenue and raised 2026 guidance confirms demand is real, but the stock's next leg depends on continued sales acceleration and de-risking the one-product concentration that leaves the thesis vulnerable to any slowdown or pricing pressure.
Description
TG Therapeutics is a commercial-stage biopharmaceutical company that develops and commercializes therapies for Bâcell malignancies and certain autoimmune disorders. Its pipeline combines monoclonal antibodies and oral small-molecule inhibitorsâtargeting Bâcell receptors and immune checkpointsâalongside early-stage programs in epigenetics and immune signaling, supported by multiple licensing and collaboration agreements with international partners. The company was incorporated in 1993 and is headquartered in New York, NY.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| May 6 | May 13 | TGTX | TG Therapeutics, Inc. | Q1 2026 revenue around $205M, full-year guidance raised to about $925M total global revenue, BRIUMVI execution remains strong, and technical momentum is favorable with about 16% 21-day gain and 17% in the last 5 sessions. | Closed | +1.6% |